Following the results of a large clinical trial involving nearly 30,000 subjects, ZyCoV-D was recently granted emergency use approval by India's national regulatory agency for subjects 12 years and above.
Under the terms of this agreement, Zydus shall transfer its manufacturing technology and provide technical assistance to Enzychem.
Both CHL and Enzychem believe that this partnership will lead to estimated manufacturing of 80m or more doses of the plasmid DNA vaccine in 2022.
Accordingly, Enzychem shall pay Zydus license fees and royalties for the commercialization of the Plasmid DNA-based COVID-19 vaccine made in Korea and exported to a number of countries, including low-medium income countries (LMICs) in Latin America and Asian New Southern Policy member countries.
Headquartered in Seoul, South Korea, Enzychem Lifesciences (KOSDAQ: 183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases.
Enzychem lead candidate, EC-18, has successfully completed US FDA phase 2 clinical testing in cancer patients.
In response to the Korean government pledge for a Vaccine Hub, Enzychem has formed a consortium with Hanmi Pharma and several domestic companies in Korea to manufacture vaccines against COVID 19.
The company plans to leverage its expertise in lipid chemistry and manufacturing to establish itself as a regional producer of lipid-based formulations for improved delivery of nucleic acids and other biologicals and drugs.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine